In an S&P Global story published April 15, 2024, ArkeaBio CEO Colin South spoke with Head of Animal Health Joseph Harvey about ArkeaBio’s plans to bring its cattle methane‑reduction vaccine to market by 2030, offering the first scalable, cost‑effective alternative to feed additives.
South and Harvey discussed how advances in biotech tools, plus new carbon‑trading rules under COP29’s Article 6, have unlocked funding and technical feasibility for a vaccine that safely stimulates cows’ immune systems to cut enteric methane without disrupting digestion or farm routines. Backed by Breakthrough Energy Ventures, ArkeaBio has demonstrated proof‑of‑concept and raised $26.5 million in Series A funding. With 80% of cattle emissions beyond feedlot reach, a vaccine could address a $15 billion market and help producers, brands, and nations meet their 2030 Scope 3 targets.
Visit https://www.spglobal.com/ for full story (subscription required).
